A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study for the Evaluation of the Safety, Tolerability, and Pharmacokinetics of Recombinant Human Plasma Gelsolin (rhu-pGSN) Following Intravenous Administration to Healthy Volunteers

Yao Liu[1], Susan L Levinson[1], Edward Kowalik[1], Jeremy Pronchik[1], Lester Kobzik[1], Mark J DiNubile[1]

Author affiliations

[1]BioAegis Therapeutics, North Brunswick, New Jersey, United States

Corresponding authors:

Dr. Susan Levinson, BioAegis Therapeutics, 685 US Highway One, North Brunswick, New Jersey, United States, email: slevinson@bioaegistx.com.

Dr. Yao Liu, BioAegis Therapeutics, 685 US Highway One, North Brunswick, New Jersey, United States, email: yliu@bioaegistx.com.

Key words: recombinant human plasma gelsolin (rhu-pGSN); acute lung injury;

immunomodulation; anti-inflammatory

ABSTRACT

Background Plasma gelsolin (pGSN) is a non-immunosuppressive anti-inflammatory

immunomodulator with demonstrated efficacy in animal models of acute lung injury. Its potential

role in moderate-to-severe acute respiratory distress syndrome (ARDS) is currently under

investigation.

Methods   We conducted a phase 1, randomized, double-blind, placebo-controlled study to

evaluate the safety, tolerability, and pharmacokinetics of recombinant human pGSN (rhu-pGSN)

following intravenous (IV) administration to healthy volunteers. Thirty-two participants were

assigned to 4 sequentially ascending dose cohorts (6, 12, 18, 24 mg/kg of body weight) to receive

five IV infusions of rhu-pGSN or saline placebo. Each cohort includes 8 subjects randomized 3:1

with rhu-pGSN or placebo. Doses were administered at 0 hours, 12 hours, 36 hours, 60 hours,

and 84 hours. The primary outcome is the incidence and severity of clinical and laboratory AEs

regardless of causality. Secondary outcomes include the pharmacokinetics of IV rhu-pGSN and

the presence of anti-rhu-pGSN antibodies at Day 28.

Results   Overall, 10 subjects (41.7%) who received rhu-pGSN reported a total of 13 adverse

events (AEs), and 1 subject (12.5%) who received placebo reported an AE. All AEs were mild or

moderate. AEs in system organ classes that were reported by 2 or more subjects in either arm

were skin and subcutaneous tissue disorders (12.5% rhu-pGSN; 0% placebo), gastrointestinal

disorders (8.3% rhu-pGSN; 0% placebo), and nervous system disorders (12.5% rhu-pGSN; 12.5%

placebo). No AEs by preferred term were reported by more than 1 subject in either arm. Three

subjects (12.5%) experienced an AE assessed as related to study drug. No serious AEs occurred,

and no AEs led to study discontinuation, dose interruption/reduction, or death. There were no

apparent between-treatment differences in laboratory abnormalities, vital signs, or

electrocardiogram findings.

Conclusions   Overall, in this study, IV rhu-pGSN (up to 24 mg/kg daily) appeared safe and well

tolerated compared to placebo. The median half-life of rhu-pGSN exceeded 14 h across all dosing

regimens, supporting once daily IV dosing in healthy subjects.

Trial registration   This study was registered with ClinicalTrials.gov on 2023-03-29 under the

registration identifier NCT05789745.

Background

Plasma gelsolin (pGSN) is a non-immunosuppressive, anti-inflammatory protein produced and secreted by virtually every cell type, and it circulates at high levels in the blood of healthy individuals (100-300 ug/ml) (1). The natural protein, and its recombinant counterpart (rhu-pGSN), are comprised of 755 amino acids and are non-glycosylated. Extensive experimental work has shown that pGSN exerts broad anti-inflammatory and host-protective effects, including scavenging extracellular actin, binding inflammatory mediators, enhancing pathogen clearance, inhibiting activation of the NLRP3 inflammasome, and promoting the transition of macrophages from a proinflammatory (M1) to an anti-inflammatory (M2) phenotype (2–8).

Circulating pGSN levels decline substantially in a wide range of acute and chronic diseases, including trauma, infections, neurologic disorders and many others (9–13). It is noteworthy that the lower the levels of plasma gelsolin, the less favorable the prognosis of acute illness becomes (9). This association has been observed in several acute lung injury (ALI) conditions, such as community-acquired pneumonia (CAP) (9), COVID-19 (14–16), ALI after cardiac bypass (17) or allogeneic stem cell transplantation (18) and ventilator weaning in critically ill patients (19).

The functional importance of pGSN in modulating inflammation is further supported by animal studies in which pGSN depletion exacerbates diseases, while rhu-pGSN administration improves outcomes across diverse models whose main common denominator is dysregulated inflammation. These include sepsis (20), arthritis (21), decompression sickness (7,22) and CO-induced neurological injury (23). Notably, rhu-pGSN has also shown consistent benefits in

preclinical models of lung injury, including bacterial pneumonia (3,24), influenza (25) and

hyperoxia (26).

Together, these findings provide two complementary lines of evidence supporting the

therapeutic potential of rhu-pGSN administration in ARDS/ALI: (1) clinical observations linking

low endogenous pGSN levels to worse outcomes, and (2) preclinical studies demonstrating

improved outcome with pGSN administration in animal models of inflammatory lung injuries.

We conducted a phase-1 clinical study to evaluate the safety, tolerability and

pharmacokinetics of rhu-pGSN in healthy volunteers, providing the foundation for the now

ongoing phase-2 trial in moderate-to-severe ARDS (NCT05947955).

Methods

Objective

The primary objective of this study (NCT05789745) was to evaluate the safety and

tolerability of 4 sequentially ascending doses of rhu-pGSN at 6 mg/kg, 12 mg/kg, 18 mg/kg and

24 mg/kg[a] of actual body weight administered by intravenous (IV) infusion for 5 doses at 0, 12,

36, 60, and 84 hours to healthy subjects. Secondary objectives include characterization of the

pharmacokinetic profile of rhu-pGSN, as well as investigation of the development of anti-pGSN

antibodies following administration of 5 doses of rhu-pGSN to healthy subjects.

Study Materials

Rhu-pGSN (BioAegis Therapeutics, North Brunswick, NJ) was produced in *Escherichia coli*

and subsequently purified and lyophilized under good manufacturing practice (GMP) procedures.

The study site received 10-ml glass vials containing lyophilized powder, which were reconstituted

with 4.9 ml of sterile water to yield approximately 5.3 ml of solution at a final concentration of 40

mg/ml[a] rhu-pGSN in a proprietary stabilizing buffer.

Study Design and Participants

This phase I, randomized, double-blind, placebo-controlled, dose escalation, parallel design study

was conducted from February 14, 2023 through May 22, 2023, by Nucleus Network at Saint Paul,

Minnesota. A total of 32 healthy volunteers aged 18 to 55 years, with body weight ≤ 100 kg, and

a body mass index < 30 kg/m^2, were enrolled. The clinical study protocol and any other

appropriate study-related documents were reviewed and approved by the Institutional Review

Board (IRB). Written informed consent was obtained from all participants. Participants were

excluded if they were pregnant or lactating women; had acute illness during the month prior to

screening; required any medications during the 5 inpatient days other than acetaminophen; were

hospitalized during the year prior to screening; had a history of cancer or treatment with

chemotherapy or radiation therapy; had a history of transplantation; had a history of diabetes

mellitus, cardiovascular disease, cerebrovascular disease, pulmonary disease, liver or kidney

disease, psychiatric condition, or active or chronic infection; received blood products during the

year prior to screening; underwent chronic mechanical ventilation or dialysis; had any clinically

significant abnormalities in clinical chemistry, hematology, urinalysis results, vital signs, EKG, or

physical examination findings as judged by the Investigator; or positive results for recreational

drugs during screening. Full inclusion and exclusion criteria are listed in the Supplementary

Materials.

Thirty-two healthy volunteers were assigned to 4 sequentially ascending dose cohorts (6,

12, 18, 24 mg/kg of body weight) to receive five IV infusions of rhu-pGSN or saline placebo (Fig.

1). Each cohort includes 8 subjects randomized 3:1 with rhu-pGSN or placebo (6 rhu-pGSN

subjects: 2 placebo subjects). Doses were administered at 0 hours (Day 1), 12 hours (Day 1), 36

hours (Day 2), 60 hours (Day 3), and 84 hours (Day 4). Subjects stayed at the study site until after

the last blood sample was taken at 108 hours (Day 5). Subjects returned for follow-up 7 days after

the initiation of therapy (on Day 8) and on Day 28 for the End-of-Study (EOS) visit. After each

cohort completed the Day 8 visit, a review of the safety results was conducted before the

initiation of the next higher dose cohort. The entire study was 28 ± 3 days in duration.

Procedures

Participants were admitted to the clinical site 1 day before study drug administration and

remained there until 24 hours after the last dosing (on Day 5). Plasma samples for

pharmacokinetic analysis were collected within 15 minutes before, and at 15 minutes and 1, 2, 4,

8 and 12 hours after Dose #1, #2 and #5, respectively; additional plasma samples were collected

at 24 hours after Dose #2 and #5. A single plasma sample for pharmacokinetic analysis was also

collected anytime on Days 8 and 28. Serum samples were collected on Day 1 before Dose #1 and

on Day 28 for assessing the presence of anti-rhu-pGSN antibodies. Participants were monitored

for adverse events (AEs), clinical laboratory measurements, vital signs, and electrocardiogram

(EKG) measurements.

Outcomes

AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version

25.1. Plasma pGSN concentrations were measured by enzyme-linked immunosorbent assay

(ELISA) as previously described (27). Since the assay measured endogenous pGSN levels as well

as exogenous rhu-pGSN, pharmacokinetic parameters were calculated for values above baseline

by subtracting pre-dose pGSN level from each observed concentration. Baseline-adjusted

concentrations that are <0 were set to 0. The pharmacokinetic parameters were calculated by

Phoenix WinNonlin version 6.3 or higher (Certara, Princeton, New Jersey), which include but not

limited to maximum concentration (C_{max}), time to maximum concentration (T_{max}), terminal half-

life ($t_{1/2}$), area under the concentration-time curve (AUC) from time 0 to 8h (AUC_{0-8}), AUC from 0

to 12h (AUC_{0-12}), AUC from 0 to 24h (AUC_{0-24}), and AUC from 0 to infinity (AUC_{0-inf}). For the

assessment of anti-rhu-pGSN antibody in serum samples, a Meso Scale Diagnosistics (MSD) based

electrochemiluminescent immunoassay was used. It utilizes the bivalent binding capability of

anti-pGSN antibodies to form a bridging complex with biotinylated Protein G and ruthenylated

pGSN to generate RLU (relative light units) for the measurement of anti-pGSN antibodies in matrix.

Samples were tested in a three-tier approach. All samples were initially evaluated in a screening

assay (Tier I) to detect the presence of antibody, samples with positive signals (signals above the

calculated screening assay cut point value) were further evaluated in a confirmatory assay (Tier

II) to determine the specificity of the reactivity. Samples confirmed positive (signals above the

confirmatory assay cut point value) were evaluated in a titration assay (Tier III) to semi-quantitate

the anti-rhu-pGSN antibody by reporting a titer.

Statistical Analysis

The sample size was 32 subjects in total: 6 subjects received rhu-pGSN and 2 subjects

received placebo in each of the 4 dosing cohorts. Data from all subjects who received placebo

were combined into a single placebo group.

Safety was assessed in all subjects who were randomized and received at least part of one

dose of study treatment (Safety Population). Pharmacokinetics were assessed in all subjects in

the safety population who had at least 1 quantifiable study drug concentration post-dose (PK

Population). The Per Protocol (PP) Population was to exclude all subjects in the Safety Population

who had missed or mistimed doses, received the wrong dose, and/or randomly discontinued the

study before the primary Day 8 visit.

Continuous variables were summarized using descriptive statistics, including the number

of subjects (N) with non-missing values, mean, standard deviation (SD), median, minimum, and

maximum. For PK data, geometric mean, coefficient of variation (CV%), and geometric coefficient

of variation (geo CV%) values were also presented. In summary tables of categorical variables,

frequency counts and percentages of subjects within each category were presented.

All statistical analysis was performed using SAS version 9.4 (SAS Institute, Cary, North

Carolina).

[a] Subsequent to conducting this study, it was determined that the extinction coefficient used

historically to determine protein concentration for plasma gelsolin underreported the actual

protein levels. Theoretical and experimental determination of the extinction coefficient confirms

that these values are underreported by 11%. Thus, this study was performed at doses that were

11% higher than reported below. The values reported here used the previous extinction

coefficient and are not adjusted.

Results

Participants

A total of 32 subjects were screened and all were randomized with rhu-pGSN (N=24; 6 in

each of the 4 cohorts) or placebo (N=8). One subject discontinued the study due to withdrawal

of consent (subject moved to another state). All other participants completed the study (Fig. 2).

The mean (SD) age of the 32 subjects was 36.2 (11.0) years (range: 20.0 to 55.0 years;

Table 1). Twenty subjects (62.5%) were male, and twelve subjects (37.5%) were female. Most

subjects were White (75.0%); the remainder of the subjects were Asian or African American

(12.5% each). The mean BMI (SD) was 24.7 (2.9).

One subject in Cohort 1 (6 mg/kg) was transgender (male to female). The gender used for

study purposes was the same as that assigned on the subject's birth certificate (male). This

ensured consistency in controlling for biological differences in physical characteristics between

the sexes, such as when measuring pharmacokinetic parameters.

Demographics and baseline characteristics were generally well balanced across rhu-pGSN

and placebo groups with the exception of gender; the ratio of male to female subjects in the

placebo group (7:1) was higher than the ratio of male to female subjects across the rhu-pGSN

groups (range: 4:2 to 3:3). Placebo recipients were younger than rhu-pGSN recipients overall.

Safety

10 of 24 subjects (41.7%) who received rhu-pGSN reported a total of 13 AEs, 11 of which

were treatment-emergent AEs (TEAEs). 1 of 8 subject (12.5%) who received placebo reported 1

AE, which was also a TEAE (Table 2). All AEs were mild or moderate. The overall proportion of

subjects with AEs was higher in the 18 and 24 mg/kg dose groups (50.0%) and lower in the 6 and

12 mg/kg dose groups (33.3%). Events in any specific system organ classes occurred in ≤3 subjects

in either arm (Table 3). AEs in system organ classes that were reported by 2 or more subjects in

either arm were skin and subcutaneous tissue disorders (12.5% rhu-pGSN; 0% placebo),

gastrointestinal disorders (8.3% rhu-pGSN; 0% placebo), and nervous system disorders (12.5%

rhu-pGSN; 12.5% placebo). No AEs by preferred term were reported by more than 1 subject in

either arm. Three subjects (12.5%) experienced an AE assessed as related (including definitely

related, probably related and possibly related) to study drug, which were constipation, fatigue,

and epigastric discomfort (Table 2, Supplementary Table 1). No AEs were serious and none led to

study discontinuation, interruption or reduction of study drug, or death. There were no clear

differences between the treatments over time in mean or median laboratory variables. Selected

summary statistics of key hematology parameters of special interest by dose group are

summarized in Supplementary Table 2. There were no between-treatment differences in vital

signs, or EKG findings, either.

Pharmacokinetics

Plasma Concentrations of rhu-pGSN

Among the 32 subjects who were randomized with rhu-pGSN (N=24) or placebo (N=8),

one subject in the 18 mg/kg group had a major protocol deviation that led to exclusion of her

data from the Per Protocol (PP) population. Summary statistics of pGSN plasma concentration

and the PK parameters are presented only for subjects who were part of both the PK and PP

populations.

The mean baseline pGSN plasma concentrations (pre-treatment on Day 1, representing

endogenous pGSN) for the 6, 12, 18, and 24 mg/kg cohorts were: 64.8, 63.6, 59.6, and 72.5

µg/mL, respectively. The mean pGSN plasma concentration for the placebo cohort at baseline

was 70.0 µg/mL (Supplementary Table 3). For each individual, concentrations above the baseline

endogenous pGSN level were calculated by subtracting the pre-dose pGSN level from each

subsequent observed concentration. Baseline-adjusted concentrations that were < 0 were set to

zero. Mean baseline-adjusted plasma rhu-pGSN concentrations were illustrated by dose group in

Fig. 3A-C. The mean maximum plasma rhu-pGSN concentrations were observed within 15

minutes after completion of treatment with the exception of Cohort 3 (18 mg/kg) which reached

mean maximum plasma rhu-pGSN concentrations after Doses 1 and 2 at 1 hour after completion

of treatment. Mean maximum plasma rhu-pGSN concentrations declined over time across

cohorts, except for Cohort 3 following Dose 1 and 2, in which the 4-hour post-dose concentrations

exceeded those observed at 2 hours. For all other cohorts and dose groups, plasma

concentrations decreased gradually at each time point over the 12- or 24-hours post-treatment.

The mean 24-hour post-dose rhu-pGSN plasma concentrations following Dose 2 and Dose 5 are

summarized in Table 4. An overall dose-dependent increase in 24-hour post-dose concentrations

was observed, except between the 18 mg/kg and 24 mg/kg cohorts after Dose 2, which may be

due to high variability in the 18 mg/kg cohort after Dose 2 (Supplementary Table 5). Mean plasma

rhu-pGSN concentrations in all cohorts had returned to near-baseline levels by Day 28 (Table 4).

Pharmacokinetic Parameters of rhu-pGSN

Key PK parameters of baseline-adjusted rhu-pGSN were summarized in Table 5. Mean PK

parameters of rhu-pGSN showed higher exposure (AUC$_{0-8}$, AUC$_{0-12}$, AUC$_{0-24}$, and AUC$_{0-inf}$) with

increasing dose except for AUC$_{0-inf}$ in Cohort 3 (18 mg/kg) after Dose 2 which was slightly higher

than the exposure observed in Cohort 4 (24 mg/kg) (13947.5 h* μg/mL and 13682.4 h* μg/mL,

respectively). This may be due to high variability in the 18 mg/kg cohort after Dose 2

(Supplementary Table 5). Mean $t_{1/2}$ (SD) varied from 9.2 (3.0) to 28.4 (8.5) hours across all doses

and cohorts and the median $t_{1/2}$ was 14.5 h in all dosing regimens, but sampling was limited to

24-h postdose measurements. The rhu-pGSN level rose well above baseline at C$_{max}$ for each dose,

with the higher doses (18 mg/kg and 24 mg/kg) yielding pGSN levels more than 10 times the

baseline values.

Immunogenicity

At day 1 (predose), 4 out of 32 subjects were screened positive in the Tier I, but none of

them was confirmed positive for the presence of anti-pGSN antibodies in the Tier II (Table 6). On

Day 28, 18 subjects were screened positive for the presence of anti-pGSN antibodies in Tier I, 2

additional samples had replicate results which spanned the cut-off point. Among the 20 samples

requiring Tier II analysis, 18 were confirmed negative, 1 in the placebo group was confirmed

positive, 1 in the 24 mg/kg rhu-pGSN group has a non-reportable result. The two samples were

further tested in Tier III, but both show near-baseline signals at the lowest dilution tested (30-

fold). Therefore, it is reasonable to consider those two samples were antibody negative.

Discussion

We assessed the safety and tolerability of rhu-pGSN in a phase 1, randomized, double-

blind, placebo-controlled, multiple-dose escalation study. Prior to this study, IV administration of

rhu-pGSN had been evaluated by BioAegis Therapeutics in two clinical trials in hospitalized

patients: one in patients with mild community-acquired pneumonia (CAP) and another in

patients with moderate to severe SARS-CoV-2(COVID-19) (27,28). In the CAP trial, 33 subjects

admitted to hospital with mild CAP received 1 to 3 doses of 6 -24 mg/kg of rhu-pGSN or placebo

over 3 days. All tested doses of rhu-pGSN were generally well tolerated in this study, with no

drug-related AEs in the rhu-pGSN arms. Two subjects died during the study: one received a single

dose of the lowest dose of rhu-pGSN, the other received placebo (27). The COVID-19 trial enrolled

61 patients with World Health Organization (WHO) severity score of 4-6 to receive adjunctive

rhu-pGSN or placebo on top of standard-of-care. Subjects in the rhu-pGSN arm received three

doses of 12 mg/kg rhu-pGSN at entry, 12 hours and 36 hours. Rhu-pGSN was well tolerated, with

numerically fewer subjects experiencing SAEs in the rhu-pGSN group (5 subjects; 16.7%) than in

the placebo group (8 subjects; 25.8%) (28).

The current study significantly expanded the safety profile characterization of pGSN

beyond that achieved in previous studies which were limited to up to three doses. In the current

study, the safety, tolerability, and pharmacokinetics of five doses of rhu-pGSN, ranging from 6

mg/kg to 24 mg/kg, were evaluated in healthy volunteers. Doses of rhu-pGSN or placebo were IV

administered at 0 h, 12 h, 36 h, 60 h and 84 h. Infusion with increasing doses of rhu-pGSN yielded

a sustained dose-dependent increase in pGSN levels in the circulation. Repeated dosing did not

lead to significant drug accumulation. In the higher rhu-pGSN dosing cohorts (18 and 24 mg/kg),

peak pGSN concentrations exceeded 10 times the physiological level, without any SAEs or AEs

that led to study discontinuation or interruption. The half-life of rhu-pGSN in different dosing

regimens varied between 9.2 h and 28.4 h, with the median half-life of rhu-pGSN exceeding 14 h

across all dosing regimens, supporting once daily IV dosing in the healthy subjects studied in this

trial. A total of 13 AEs were reported by 10 of 24 subjects (41.7%) who received rhu-pGSN,

whereas 1 AE was reported by 1 of 8 subject (12.5%) who received placebo. All AEs were mild or

moderate. No apparent association was observed between the rhu-pGSN dose and the frequency

or types of AEs reported.

Conclusions

Overall, IV administration of five doses of rhu-pGSN up to 24 mg/kg over 5 days was safe

and well tolerated in this small trial in healthy volunteers. In the higher dosing cohorts, even with

pGSN levels maintained well above physiological concentration over the 5 days, neither SAEs nor

AEs that led to study discontinuation/interruption were observed. The median half-life of rhu-

pGSN exceeded 14 h across all dosing regimens, supporting once daily IV dosing in healthy

subjects. A phase 2 proof-of-concept trial evaluating the efficacy and safety of rhu-pGSN in

addition to standard of care in subject with moderate-to severe ARDS due to pneumonia or other

infections is currently ongoing.

List of abbreviations

AE	adverse events
ALI	acute lung injury
ARDS	acute respiratory distress syndrome

BMI	body mass index
CAP	community-acquired pneumonia
EKG	electrocardiogram
ELISA	enzyme-linked immunosorbent assay
EOS	End of Study
IRB	Institutional Review Board
IV	intravenous
MedDRA	Medical Dictionary for Regulatory Activities
PK	pharmacokinetic(s)
PP	Per Protocol
rhu-pGSN	recombinant human plasma gelsolin
SAE	serious adverse event
TEAE	treatment-emergent adverse event

Declarations

Human ethics approval and consent to participate declaration

The study was designed and conducted in accordance with the Declaration of Helsinki and was approved by Advarra's Institutional Review Board (IRB# Pro00069641) before the start of the trial. Written informed consent was obtained from all participants.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding

author on reasonable request.

Competing interests

Y.L., S.L.L., E.K., J.P. are employees of BioAegis Therapeutics, which is developing recombinant

human plasma gelsolin (rhu-pGSN) for clinical use. L. K. is a paid consultant to BioAegis and owns

stock in the company. S. L. L. is the Chief Executive Officer and M. J. D. was the Chief Medical

Officer at the time of the study, both of whom own stock in the company.

Funding

BioAegis Therapeutics funded the study. The trial was designed and managed by BioAegis

Therapeutics in collaboration with a CRO.

Authors' contribution

YL analyzed and interpreted the data, and wrote the first draft of the manuscript. SL and MJD

contributed to the design, execution and data analysis of the clinical trial. EK and JP performed

the plasma gelsolin ELISA. LK contributed to manuscript writing. All coauthors reviewed and

approved the final version of the manuscript.

Acknowledgements

Recombinant human plasma gelsolin was provided by BioAegis Therapeutics.

We thank Nucleus Network for invaluable help conducting the trial and Jennifer Stanley for CSR

preparation.

We also thank all the healthy volunteers who participated in the trial, as well as the principal

investigator at the study site: Trisha Shamp (Saint Paul, Minnesota).

References

1.   Smith DB, Janmey PA, Herbert TJ, Lind SE. Quantitative measurement of plasma gelsolin and
its incorporation into fibrin clots. J Lab Clin Med. 1987 Aug;110(2):189–95.

2.   Ordija CM, Chiou TTY, Yang Z, Deloid GM, de Oliveira Valdo M, Wang Z, et al. Free actin
impairs macrophage bacterial defenses via scavenger receptor MARCO interaction with
reversal by plasma gelsolin. American Journal of Physiology–Lung Cellular and Molecular
Physiology. 2017;312(6):L1018–28.

3.   Yang Z, Chiou TTY, Stossel TP, Kobzik L. Plasma gelsolin improves lung host defense against
pneumonia by enhancing macrophage NOS3 function. American Journal of Physiology–Lung
Cellular and Molecular Physiology. 2015;309(1):L11–6.

4.   Osborn TM, Dahlgren C, Hartwig JH, Stossel TP. Modifications of cellular responses to
lysophosphatidic acid and platelet-activating factor by plasma gelsolin. American Journal of
Physiology-Cell Physiology. 2007;292(4):C1323–30.

5.   Bucki R, Georges PC, Espinassous Q, Funaki M, Pastore JJ, Chaby R, et al. Inactivation of
endotoxin by human plasma gelsolin. Biochemistry. 2005;44(28):9590–7.

6.   Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding
protein in clearing actin from the circulation. The Journal of Clinical Investigation.
1986;78(3):736–42.

7.   Bhopale VM, Ruhela D, Brett KD, Nugent NZ, Fraser NK, Levinson SL, et al. Plasma gelsolin
modulates the production and fate of IL-1β-containing microparticles following high-
pressure exposure and decompression. Journal of Applied Physiology. 2021;130(5):1604–13.

8.   Sharma RK, Goswami B, Das Mandal S, Guha A, Willard B, Ray PS. Quorum sensing by
gelsolin regulates programmed cell death 4 expression and a density-dependent phenotype
in macrophages. The Journal of Immunology. 2021;207(5):1250–64.

9.   Self WH, Wunderink RG, DiNubile MJ, Stossel TP, Levinson SL, Williams DJ, et al. Low
admission plasma gelsolin concentrations identify community-acquired pneumonia patients
at high risk for severe outcomes. Clinical Infectious Diseases. 2019;69(7):1218–25.

353 10. Mounzer KC, Moncure M, Smith YR, DiNubile MJ. Relationship of admission plasma gelsolin
354    levels to clinical outcomes in patients after major trauma. American Journal of Respiratory
355    and Critical Care Medicine. 1999;160(5):1673–81.

356 11. Güntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL, et al. Plasma
357    gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. Journal of
358    Alzheimer's Disease. 2010;21(2):585–96.

359 12. Kulakowska A, Drozdowski W, Sadzynski A, Bucki R, Janmey PA. Gelsolin concentration in
360    cerebrospinal fluid from patients with multiple sclerosis and other neurological disorders.
361    European Journal of Neurology. 2008;15(6):584–8.

362 13. Osborn TM, Verdrengh M, Stossel TP, Tarkowski A, Bokarewa M. Decreased levels of the
363    gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Research & Therapy.
364    2008;10(5):R117.

365 14. Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, Jesus AAA de, et al. An immune-based
366    biomarker signature is associated with mortality in COVID-19 patients. JCI Insight [Internet].
367    2021 Jan 11 [cited 2026 Jan 23];6(1). Available from:
368    https://insight.jci.org/articles/view/144455

369 15. Messner CB, Demichev V, Wendisch D, Michalick L, White M, Freiwald A, et al. Ultra-high-
370    throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Systems.
371    2020;11(1):11–24.

372 16. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, et al. Large-
373    scale multi-omic analysis of COVID-19 severity. Cell Systems. 2021;12(1):23–40.

374 17. Shi S, Chen C, Zhao D, Liu X, Cheng B, Wu S, et al. The role of plasma gelsolin in
375    cardiopulmonary bypass–induced acute lung injury in infants and young children: a pilot
376    study. BMC Anesthesiology. 2014;14(1):67.

377 18. DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH. Prognostic implications of
378    declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood.
379    2002;100(13):4367–71.

380 19. Holm FS, Sivapalan P, Seersholm N, Itenov TS, Christensen PH, Jensen JUS. Acute lung injury
381    in critically ill patients: actin-scavenger gelsolin signals prolonged respiratory failure. Shock.
382    2019;52(3):370–7.

383 20. Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Plasma gelsolin is a
384    marker and therapeutic agent in animal sepsis. Critical Care Medicine. 2007;35(3):849–55.

385 21. Lee J, Sasaki F, Koike E, Cho M, Lee Y, Dho SH, et al. Gelsolin alleviates rheumatoid arthritis
386    by negatively regulating NLRP3 inflammasome activation. Cell Death & Differentiation.
387    2024;31(12):1679–94.

22. Bhat AR, Arya AK, Bhopale VM, Imtiyaz Z, Thom SR. Recombinant human plasma gelsolin
suppresses persistent neuroinflammation and restores hippocampal neurogenesis in murine
model of decompression sickness. Journal of Neurophysiology. 2024;132(6):1877–86.

23. Arya AK, Sethuraman K, Waddell J, Cha YS, Liang Y, Bhopale VM, et al. Inflammatory
responses to acute carbon monoxide poisoning and the role of plasma gelsolin. Sci Adv.
2025 Feb 7;11(6):eado9751.

24. DiNubile MJ, Levinson SL, Stossel TP, Lawrenz MB, Warawa JM. Recombinant human plasma
gelsolin improves survival and attenuates lung injury in a murine model of multidrug-
resistant Pseudomonas aeruginosa pneumonia. Open Forum Infectious Diseases.
2020;7(8):ofaa236.

25. Yang Z, Bedugnis A, Levinson S, DiNubile M, Stossel T, Lu Q, et al. Delayed administration of
recombinant plasma gelsolin improves survival in a murine model of penicillin-susceptible
and penicillin-resistant pneumococcal pneumonia. The Journal of Infectious Diseases.
2019;220(9):1498–502.

26. Cui TX, Brady AE, Zhang YJ, Fulton CT, Popova AP. Gelsolin attenuates neonatal hyperoxia-
induced inflammatory responses to rhinovirus infection and preserves alveolarization.
Frontiers in Immunology. 2022;13:792716.

27. Tannous A, Levinson SL, Bolognese J, Opal SM, DiNubile MJ. Safety and Pharmacokinetics of
Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-
Acquired Pneumonia. Antimicrobial Agents and Chemotherapy. 2020 Sept
21;64(10):10.1128/aac.00579-20.

28. DiNubile MJ, Parra S, Salomó AC, Levinson SL. Adjunctive Recombinant Human Plasma
Gelsolin for Severe Coronavirus Disease 2019 Pneumonia. Open Forum Infectious Diseases.
2022 Aug 2;9(8):ofac357.

420   **Tables**

421   **Table 1. Subject demographics**

Parameter	rhu-pGSN				Placebo N=8	Overall N=32
	6 mg/kg N=6	12 mg/kg N=6	18 mg/kg N=6	24 mg/kg N=6		
Age (yr)						
Mean (SD)	35.3 (10.2)	42.2 (4.1)	37.7 (14.7)	37.0 (15.4)	30.5 (7.4)	36.2 (11.0)
Median	34.0	41.5	36.0	37.5	28.5	36.5
Range	25-54	38-48	20-55	20-52	21-43	20-55
Gender, n (%)						
Male	4 (66.7)	3 (50.0)	3 (50.0)	3 (50.0)	7 (87.5)	20 (62.5)
Female	2 (33.3)	3 (50.0)	3 (50.0)	3 (50.0)	1 (12.5)	12 (37.5)
Ethnicity, n (%)						
Not Hispanic or Latino	4 (66.7)	5 (83.3)	6 (100)	5 (83.3)	7 (87.5)	27 (84.4)
Hispanic or Latino	2 (33.3)	1 (16.7)	0	1 (16.7)	1 (12.5)	5 (15.6)
Race, n (%)						
Asian	0	0	1 (16.7)	3 (50.0)	0	4 (12.5)
Black or African American	1 (16.7)	1 (16.7)	0	0	2 (25.0)	4 (12.5)
White	5 (83.3)	5 (83.3)	5 (83.3)	3 (50.0)	6 (75.0)	24 (75.0)
BMI (kg/m^2)						
Mean (SD)	24.6 (2.9)	24.8 (3.5)	25.3 (3.7)	25.4 (2.9)	23.9 (2.0)	24.7 (2.9)
Median	24.5	24.7	26.6	26.0	23.9	24.8
Range	19.5-27.9	20.8-28.8	19.0-29.7	21.9-29.1	21.2-26.4	19.0-29.7

426 **Table 2. Overview of adverse events in the Safety Population**

Parameter	rhu-pGSN					Placebo N=8
	6 mg/kg N=6	12 mg/kg N=6	18 mg/kg N=6	24 mg/kg N=6	Combined N=24	
No. of AEs	2	3	5	3	13	1
No. of Treatment-emergent AEs (TEAEs)	1	3	5	2	11	1
No. (%) of subjects with at least 1:						
AE	2 (33.3)	2[a] (33.3)	3[b] (50.0)	3 (50.0)	10 (41.7)	1 (12.5)
Serious AE	0	0	0	0	0	0
AE leading to study discontinuation	0	0	0	0	0	0
AE leading to study interruption	0	0	0	0	0	0
AE leading to death	0	0	0	0	0	0
TEAE	1 (16.7)	2 (33.3)	3 (50.0)	2 (33.3)	8 (33.3)	1 (12.5)
No. (%) of subjects with AEs by NCI-CTCAE grade						
1 - Mild	1 (16.7)	2[a] (33.3)	3[b] (50.0)	2 (33.3)	8 (33.3)	1 (12.5)
2 - Moderate	1 (16.7)	1[a] (16.7)	0	1 (16.7)	3 (12.5)	0
3 - Severe	0	0	0	0	0	0
4 - Life-threatening	0	0	0	0	0	0
5 - Fatal	0	0	0	0	0	0
No. (%) of subjects with AEs by relationship to study drug						
Definitely unrelated	2 (33.3)	2[a] (33.3)	2[b] (33.3)	2 (33.3)	8 (33.3)	0
Probably unrelated	0	0	1[b] (16.7)	0	1 (4.2)	1 (12.5)
Possibly related	0	0	2[b] (33.3)	1 (16.7)	3 (12.5)	0
Probably related	0	0	0	0	0	0
Definitely related	0	0	0	0	0	0
No. (%) of subjects with AEs by relationship to study procedure						
Definitely unrelated	1 (16.7)	2[a] (33.3)	3[b] (50.0)	3 (50.0)	9 (37.5)	1 (12.5)
Probably unrelated	0	0	1[b] (16.7)	0	1 (4.2)	0
Possibly related	0	0	0	0	0	0
Probably related	0	0	0	0	0	0
Definitely related	1 (16.7)	1[a] (16.7)	0	0	2 (8.3)	0

[a]One subject experienced two AEs: one mild and one moderate. Both AEs were deemed definitely
unrelated to study drug. One AE was deemed definitely unrelated to study procedure, the other
definitely related.

[b]One subject experienced three AEs, all of which were mild. One AE was deemed definitely unrelated to
study drug, one probably unrelated, and one possibly related. Three AEs were deemed definitely
unrelated to study procedure, and one probably unrelated.
433
434 **Table 3. Summary of adverse events by System Organ Class and Preferred Term in the Safety**
435 **Population**

| System Organ Class Preferred Term | rhu-pGSN | | | | | Placebo N=8 No. (%) |
	6 mg/kg N=6 No. (%)	12 mg/kg N=6 No. (%)	18 mg/kg N=6 No. (%)	24 mg/kg N=6 No. (%)	Combined N=24 No. (%)	
Skin and subcutaneous tissue disorders	0	1 (16.7)	1 (16.7)	1 (16.7)	3 (12.5)	0
Dermatitis	0	0	0	1 (16.7)	1 (4.2)	0
Ecchymosis	0	1	0	0	1 (4.2)	0
Rash	0	0	1 (16.7)	0	1 (4.2)	0
Gastrointestinal disorders	0	0	1 (16.7)	1 (16.7)	2 (8.3)	0
Constipation	0	0	1 (16.7)	0	1 (4.2)	0
Epigastric discomfort	0	0	0	1 (16.7)	1 (4.2)	0
Nervous system disorders	1 (16.7)	1 (16.7)	0	1 (16.7)	3 (12.5)	1 (12.5)
Dizziness	1 (16.7)	0	0	0	1 (4.2)	0
Headache	0	0	0	1 (16.7)	1 (4.2)	1 (12.5)
Muscle contractions involuntary	0	1	0	0	1 (4.2)	0
General disorders and administration site conditions	0	0	1 (16.7)	0	1 (4.2)	0
Fatigue	0	0	1 (16.7)	0	1 (4.2)	0
Infections and infestations	0	1 (16.7)	0	0	1 (4.2)	0
Urinary tract infection	0	1 (16.7)	0	0	1 (4.2)	0
Injury, poisoning and procedural complications	1 (16.7)	0	0	0	1 (4.2)	0
Muscle strain	1 (16.7)	0	0	0	1 (4.2)	0
Musculoskeletal and connective tissue disorders	0	0	1 (16.7)	0	1 (4.2)	0
Arthralgia	0	0	1 (16.7)	0	1 (4.2)	0

Table 4. Mean baseline-adjusted plasma concentrations of rhu-pGSN at 24 hours post-dose, and on Day 8 and 28 in subjects who were part of both the PK and PP populations

Time Points	rhu-pGSN				Placebo N=8
	6 mg/kg N=6	12 mg/kg N=6	18 mg/kg N=5[a]	24 mg/kg N=6	
24-hour post Dose 2	72.3 (19.3)	142.7 (24.5)	218.0 (74.6)	204.5 (50.1)	1.6 (4.6)
24-hour post Dose 5	125.9 (58.0)	156.9 (19.4)	228.0 (29.5)	269.4 (26.2)	2.7 (5.4)
Day 8	36.0 (23.0)	40.5 (16.2)	46.4 (23.6)	46.9 (24.2)	6.1 (6.7)
Day 28	19.7 (16.3)	8.4 (9.5)	18.5 (7.7)	9.3 (10.7)	4.2 (6.1)

[a] One subject in the 18 mg/kg group had a major protocol deviation that led to exclusion of her data from the Per Protocol (PP) population.

Table 5. Summary of mean pharmacokinetics parameters in subjects who were part of both the PK and PP populations

Geometric Mean Parameters (SD)	rhu-pGSN			
	6 mg/kg N=6	12 mg/kg N=6	18 mg/kg N=5[a]	24 mg/kg N=6
Dose 1				
C_{max} (µg/mL)[b]	148.4 (26.8)	347.5 (41.2)	442.5 (50.2)	663.6 (110.8)
AUC_{0-8} (h*µg/mL)[b]	912.4 (201.9)	2010.0 (261.8)	2659.9 (474.3)	2695.6 (475.1)
AUC_{0-12} (h*µg/mL)[b]	1245.5 (257.9)	2737.5 (379.1)	3547.0 (657.3)	4832.3 (646.6)
$t_{1/2}$ (h)	14.0 (5.4)	13.1 (2.6)	9.2 (3.0)	10.7 (5.2)
Dose 2				
C_{max} (µg/mL)[b]	225.2 (27.0)	506.9 (78.5)	691.5 (110.5)	855.7 (200.6)
AUC_{0-8} (h*µg/mL)[b]	1422.9 (179.6)	3089.9 (388.7)	4389.6 (851.8)	5132.3 (1013.6)
AUC_{0-12} (h*µg/mL)[b]	1953.6 (234.5)	4194.6 (448.6)	6022.1 (1376.2)	6859.8 (1318.6)
AUC_{0-24} (h*µg/mL)[b]	3066.2 (256.8)	6448.5 (599.5)	9374.2 (2456.0)	10258.2 (2035.6)
AUC_{0-inf} (h*µg/mL)[b]	4857.8 (933.3)	9394.8 (1641.5)	13947.5 (4245.5)	13682.4 (3094.3)
$t_{1/2}$ (h)	16.7 (6.1)	14.5 (3.4)	15.1 (4.5)	12.0 (1.5)
Dose 5				
C_{max} (µg/mL)[b]	218.9 (37.7)	501.6 (60.4)	703.8 (140.7)	970.9 (87.9)
AUC_{0-8} (h*µg/mL)[b]	1371.8 (252.5)	3033.3 (329.1)	4257.9 (561.1)	5750.0 (539.1)
AUC_{0-12} (h*µg/mL)[b]	1958.7 (463.3)	4131.6 (579.1)	5770.0 (632.3)	7824.6 (816.2)
AUC_{0-24} (h*µg/mL)[b]	3486.5 (1035.2)	6599.1 (1334.2)	9139.1 (793.1)	12135.3 (1172.4)
AUC_{0-inf} (h*µg/mL)[b]	6634.8 (2055.4)	12006.2 (7502.8)	14909.2 (1294.6)	17779.1 (1810.9)
$t_{1/2}$ (h)	28.4 (8.5)	22.0 (11.3)	17.6 (1.9)	14.5 (2.2)

[a] One subject in the 18 mg/kg group had a major protocol deviation that led to exclusion of her data from the Per Protocol (PP) population.

[b] Baseline pGSN concentrations (pre-Dose 1, Day 1) were subtracted from each observed concentration of each subject.

453 **Table 6 Frequencies of anti-drug antibodies at day 1 (predose) and day 28 in different cohorts**

	rhu-pGSN				Placebo	Total
	6 mg/kg No.	12 mg/kg No.	18 mg/kg No.	24 mg/kg No.	No.	No.
D1						
Tested	6	6	6	6	8	32
Screened positive in Tier I	0	1	0	1	2	4
Confirmed positive in Tier II	0	0	0	0	0	0
D28						
Tested	6	6	6	6	8	32
Screened positive in Tier I	2[a]	4	5	5[b]	2	18
Confirmed positive in Tier II	0	0	0	0[c]	1	1
Considered as positive after Tier III	0	0	0	0	0	0

454 [a]One additional sample has two replicates spanning the cut-off point and therefore tested in Tier II
455 [b]One additional sample has two replicates spanning the cut-off point and therefore tested in Tier II
456 [c]One additional sample has a non-reportable Tier II result, which was further tested in Tier III
457

Figures

Fig 1. Study design and dosing regimen

Fig 2. Patient disposition

[a]One subject discontinued the study due to withdrawal of consent (subject moved to another state)

Fig. 3 Mean baseline-adjusted plasma rhu-pGSN concentrations following dose 1 (A), dose 2
(B) and dose 5 (C) in subjects who were part of both the PK and PP populations

Supplemental Materials

Additional file 1. Study protocol

Additional file 2. Inclusion and exclusion criteria, Supplementary Table 1-6